Although mutations in these methyltransferases are not common in brain tumors, mutations or amplification in receptor tyrosine kinase (RTK) genes may drive abnormal DNA methylation patterns in gliomas, encompassing metabolic reprogramming and contributing to the distinct hypomethylation phenotype observed. The gene discussed is NTRK1; the disease is brain neoplasm.